Literature DB >> 30780849

miRNAs and diabetes mellitus.

Dwi Setyowati Karolina1, Arunmozhiarasi Armugam1, Sugunavathi Sepramaniam1, Kandiah Jeyaseelan2.   

Abstract

Diabetes is a chronic disease that manifests when insulin production by the pancreas is insufficient or when the body cannot effectively utilize the secreted insulin. The onset of diabetes often goes undetected until the later stages where subsequent glucose accumulation in the system (hyperglycemia) is observed. Over time, it leads to serious multi-organ damage, especially to the nerves and blood vessels. The WHO reports that approximately 346 million people worldwide are diagnosed with diabetes. With no cure available, long-term medical care for diabetes has become a global economic challenge globally. Hence, there is a need to explore novel early biomarkers and therapeutics for diabetes. One such potential molecule is the miRNAs. miRNAs are endogenous, noncoding RNAs that predominantly inhibit gene expression. Compelling evidence showed that altered miRNA expressions are linked to pathological conditions, including diabetes manifestation. This review focuses on the implications of miRNAs in diabetes and their related complications.

Entities:  

Keywords:  diabetes; gene regulators; insulin signaling; lipid metabolism; miRNAs

Year:  2012        PMID: 30780849     DOI: 10.1586/eem.12.21

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  5 in total

1.  MiR-409-3p targets a MAP4K3-ZEB1-PLGF signaling axis and controls brown adipose tissue angiogenesis and insulin resistance.

Authors:  Dakota Becker-Greene; Hao Li; Daniel Perez-Cremades; Winona Wu; Furkan Bestepe; Denizhan Ozdemir; Carolyn E Niosi; Ceren Aydogan; Dennis P Orgill; Mark W Feinberg; Basak Icli
Journal:  Cell Mol Life Sci       Date:  2021-10-26       Impact factor: 9.261

2.  Clinical Role of Serum miR107 in Type 2 Diabetes and Related Risk Factors.

Authors:  Diana Šimonienė; Darius Stukas; Albertas Daukša; Džilda Veličkienė
Journal:  Biomolecules       Date:  2022-04-08

3.  New Insights on the Regulation of the Insulin-Degrading Enzyme: Role of microRNAs and RBPs.

Authors:  Yolanda Martín-Martín; Ana Pérez-García; Marta Torrecilla-Parra; Mario Fernández-de Frutos; Virginia Pardo-Marqués; María José Casarejos; Rebeca Busto; Cristina M Ramírez
Journal:  Cells       Date:  2022-08-16       Impact factor: 7.666

4.  Serum microRNA-33 levels in pre-diabetic and diabetic patients.

Authors:  Beydolah Shahouzehi; Mostafa Eghbalian; Hossein Fallah; Soheil Aminizadeh; Yaser Masoumi-Ardakani
Journal:  Mol Biol Rep       Date:  2021-06-19       Impact factor: 2.316

5.  Effects of synbiotic supplementation on gut microbiome, serum level of TNF-α, and expression of microRNA-126 and microRNA-146a in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomized clinical trial.

Authors:  Fahime Zeinali; Seyed Mohsen Aghaei Zarch; Mohammad Yahya Vahidi Mehrjardi; Seyed Mehdi Kalantar; Alireza Jahan-Mihan; Elham Karimi-Nazari; Hossein Fallahzadeh; Mahdieh Hosseinzadeh-Shamsi-Anar; Masoud Rahmanian; Mohammad Reza Fazeli; Hassan Mozaffari-Khosravi
Journal:  Trials       Date:  2020-04-14       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.